My favorite trial is a negative one. It’s ENZARAD. ENZARAD is high-risk localized disease, treated with radiotherapy plus ADT and adding eventually an RP. That trial shows there is no benefit of RP. It’s very important. Why? Because following the STAMPEDE trial we saw high-risk patients not being in the very high risk receiving a combination of ADT and Abiraterone...
My favorite trial is a negative one. It’s ENZARAD. ENZARAD is high-risk localized disease, treated with radiotherapy plus ADT and adding eventually an RP. That trial shows there is no benefit of RP. It’s very important. Why? Because following the STAMPEDE trial we saw high-risk patients not being in the very high risk receiving a combination of ADT and Abiraterone. Today we have almost, I mean the ENZARAD has almost demonstrated that it’s wrong. That if you have a high-risk localized disease, negative lymph nodes, you’re going to be treated as well with radiotherapy and two years of standard hormone therapy. So that’s typically a negative, statistically negative trial with a very, very high clinical significance. So very important trial. I would even say going back tomorrow to my practice, that’s the most informative trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
